- Drug Manufacturers - Specialty & Generic
- Healthcare
-
-0.54
EPS
-
-21.00
P/E
-
13.6B
MARKET CAP
-
4.21%
DIV YIELD
Company Overview
1000 MYLAN BOULEVARD,CANONSBURG PA 15317,(724) 514-1465
CEO
Mr. Scott Andrew Smith
Employess
33000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.viatris.com
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Next Earnings Date
Nov. 5, 2024
Ex Dividends date
Sep. 13, 2024
Dividend Date
Aug. 23, 2024
YTD Performance
0.00%
Fiscal Year End
12-31
IPO Date
1980-03-17
Growth Rates
(avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
---|---|---|---|---|
Sales/Revenue | 8.33% | 6.11% | 8.79% | -5.42% |
EPS | -30.07% | -41.92% | 26.85% | -97.33% |
Equity | 21.41% | 10.96% | -3.75% | -2.87% |
Cash | 13.05% | 20.69% | 5.57% | -21.14% |
Return On Capital (ROIC) | 1.96% | -3.54% | -5.63% | 1.43% |
Debt
year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Short Term Debt | 2,030 | 1,260 | 1,880 | 3,450 | 1,510 |
Long Term Debt | 16,200 | 18,000 | 19,700 | 22,700 | 11,200 |
LT Finance Leases | 165 | 262 | 288 | 322 | 252 |
Shares Outstanding | 1,200 | 1,210 | 1,210 | 601 | 516 |
Market Cap | 13,000 | 13,500 | 16,400 | 11,300 | 10,400 |
Price
News
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
1 monthThe headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.comUS Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
1 monthOn Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
benzinga.comWhy Viatris Stock Is Jumping Today
1 monthViatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.
fool.comViatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
1 monthViatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
zacks.comViatris (VTRS) Q2 Earnings Surpass Estimates
1 monthViatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.
zacks.comViagra-maker Viatris beats Q2 estimates on branded and generic drug demand
1 monthDrugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.
reuters.comViatris Reports Second Quarter Financial Results for 2024
1 monthPITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1] Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2] Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder Return Raises 2024 Full-Year New Product Revenues Range to $500 Million-$600 Million Expects 2024 Full-Year Total Revenues Growth of ~2% on a Divestiture-Adjusted Operational Basis[3] Viatris Inc. (NASDAQ: VTRS) today announced strong financial results for the second quarter of 2024, including total revenues of $3.8 billion and new product revenues of $210 million, demonstrating the Company's ability to continue to grow its diversified base business. With the substantial completion of its divestitures the Company believes it has increased its financial strength and has a strong foundation from which to accelerate growth and shareholder return.
prnewswire.comViatris Announces Second Quarter 2024 Dividend
1 monthPITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024.
prnewswire.comNovartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
1 monthNovartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
reuters.comWill These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
1 monthLet's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
zacks.comSeeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
1 monthLooking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
zacks.comEarnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline
2 monthsViatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com